These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms]. Oka Y; Tsuboi A; Nishida S; Hosen N; Nakata J; Hashii Y; Maeda T; Oji Y; Kumanogoh A; Sugiyama H Rinsho Ketsueki; 2011 May; 52(5):235-42. PubMed ID: 21646768 [No Abstract] [Full Text] [Related]
4. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Baron F; Storb R Best Pract Res Clin Haematol; 2006; 19(4):637-53. PubMed ID: 16997174 [TBL] [Abstract][Full Text] [Related]
5. Guest editorial: Immunotherapy for hematological malignancies: the quest to overcome tolerogenic drive. Kadowaki N Int J Hematol; 2014 Feb; 99(2):105-6. PubMed ID: 24395282 [No Abstract] [Full Text] [Related]
6. T cell modulation in immunotherapy for hematological malignancies. Lin C; Chen S; Li Y Cell Biol Toxicol; 2017 Aug; 33(4):323-327. PubMed ID: 28474249 [No Abstract] [Full Text] [Related]
12. Immunotherapy of hematological malignancies: what is new? OrtÃn M Ann Oncol; 2005; 16 Suppl 2():ii53-62. PubMed ID: 15958476 [No Abstract] [Full Text] [Related]
13. Immunotherapy of hematologic malignancies: the road to the future. Sotomayor EM; Loughran TP Cancer Control; 2002; 9(2):97-8. PubMed ID: 11965230 [No Abstract] [Full Text] [Related]
14. [Progress in Immunotherapy for Hematological Malignancies]. Yasukawa M Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):1061-8. PubMed ID: 30168700 [No Abstract] [Full Text] [Related]
15. [The role of immunotherapy in the treatment of patients with hematologic neoplasms]. Rukavitsyn OA Vopr Onkol; 2002; 48(2):186-92. PubMed ID: 12227066 [No Abstract] [Full Text] [Related]